Bacopa monnieri  (Brahmi) improved novel object recognition task and increased cerebral vesicular glutamate transporter type 3 in sub‐chronic phencyclidine rat model of schizophrenia | Zendy

Piyabhan Pritsana | Zendy; Wannasiri Supaporn | Zendy; Naowaboot Jarinyaporn | Zendy

Premium

Bacopa monnieri (Brahmi) improved novel object recognition task and increased cerebral vesicular glutamate transporter type 3 in sub‐chronic phencyclidine rat model of schizophrenia

Author(s) -

Piyabhan Pritsana,

Wannasiri Supaporn,

Naowaboot Jarinyaporn

Publication year - 2016

Publication title -

clinical and experimental pharmacology and physiology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.752

H-Index - 103

eISSN - 1440-1681

pISSN - 0305-1870

DOI - 10.1111/1440-1681.12658

Subject(s) - medicine , neuroprotection , phencyclidine , cognitive deficit , prefrontal cortex , schizophrenia (object oriented programming) , pharmacology , cognition , neuroscience , psychiatry , nmda receptor , psychology , cognitive impairment , receptor

Summary Reduced vesicular glutamate transporter 1 ( VGLUT 1) and 2 ( VGLUT 2) indicate glutamatergic hypofunction leading to cognitive impairment in schizophrenia. However, VGLUT 3 involvement in cognitive dysfunction has not been reported in schizophrenia. Brahmi ( Bacopa monnieri ) might be a new treatment and prevention for cognitive deficits in schizophrenia by acting on cerebral VGLUT 3 density. We aimed to study cognitive enhancement‐ and neuroprotective‐effects of Brahmi on novel object recognition and cerebral VGLUT 3 immunodensity in sub‐chronic (2 mg/kg, Bid, ip) phencyclidine ( PCP ) rat model of schizophrenia. Rats were assigned to three groups for cognitive enhancement effect study: Group 1, Control; Group 2, PCP administration; Group 3, PCP+Brahmi. A neuroprotective‐effect study was also carried out. Rats were again assigned to three groups: Group 1, Control; Group 2, PCP administration; Group 3, Brahmi+PCP. Discrimination ratio ( DR ) representing cognitive ability was obtained from a novel object recognition task. VGLUT 3 immunodensity was measured in the prefrontal cortex, striatum and cornu ammonis fields 1–3 (CA1–3) using immunohistochemistry. We found reduced DR in the PCP group, which occurred alongside VGLUT 3 reduction in all brain areas. PCP +Brahmi showed higher DR score with increased VGLUT 3 immunodensity in the prefrontal cortex and striatum. Brahmi+ PCP group showed a higher DR score with increased VGLUT 3 immunodensity in the prefrontal cortex, striatum and CA1–3. We concluded that reduced cerebral VGLUT 3 was involved in cognitive deficit in PCP ‐administrated rats. Receiving Brahmi after PCP restored cognitive deficit by increasing VGLUT 3 in the prefrontal cortex and striatum. Receiving Brahmi before PCP prevented cognitive impairment by elevating VGLUT 3 in prefrontal cortex, striatum and CA1–3. Therefore, Brahmi could be a new frontier of restoration and prevention of cognitive deficit in schizophrenia.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research